Skip to main content

Lupus

      #IL2 #Rx in active #SLE?
      Maybe 🤔

      IL2 is tricky - low dose May help #SLE but too much of a good thing may have a neg

      Janet Pope Janetbirdope

      3 months ago
      #IL2 #Rx in active #SLE? Maybe 🤔 IL2 is tricky - low dose May help #SLE but too much of a good thing may have a neg impact. RCT of IL2i in #SLE gave a good dose response and improved TRegs. #ACRBest #ACR25 @RheumNow @ACRheum #LB01 https://t.co/F61qz5x5We
      #ACR25 Abstr#LB10 Promising 4-Year data of Deucravacitinib in blinded phase 2 RCT +LTE study showed efficacy inc. LLDAS

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 months ago
      #ACR25 Abstr#LB10 Promising 4-Year data of Deucravacitinib in blinded phase 2 RCT +LTE study showed efficacy inc. LLDAS and CLASI-50 response were maintained/improved over time in #SLE No concerning safety signal. Looking forward to Phase 3 results next year @RheumNow https://t.co/fZv82zJ6Q4
      #ACR25 How hard will you go & at what cost? A study in China using CD20/BCMA Bispecific autologous CAR-T showed prof

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 months ago

      #ACR25 How hard will you go & at what cost? A study in China using CD20/BCMA Bispecific autologous CAR-T showed profound depletion, normalisation of abs and good response in #SLE (10/11 had LN). But 2 had G3 infections & cytopenia. Presenters said some had IVIG @RheumNow #ACRBest https://t.co/TF0wpib5rr

      Data from this retrospective cohort study by Alomari et al show that SLE pts on SGLT2is
      ⬇️rates of PulHPN (OR 0.79)

      sheila RHEUMarampa

      3 months ago
      Data from this retrospective cohort study by Alomari et al show that SLE pts on SGLT2is ⬇️rates of PulHPN (OR 0.79) ⬇️all-cause mortality (0.49) ⬇️hospitalizations (OR 0.56) ⬇️LN (OR 0.4) vs non-SGLT2i users(p<0.001) Impt role of SGLT2i as adjunct tx #ACR25 @RheumNow Abs2438 https://t.co/NQJTzQwRCt
      #ACR25 Abstr#LB01 After several smaller studies, a Multicentre, Phase 2b RCT of 152 #SLE pts in China. SRI-4 was met in

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 months ago
      #ACR25 Abstr#LB01 After several smaller studies, a Multicentre, Phase 2b RCT of 152 #SLE pts in China. SRI-4 was met in IL-2 as s/c every other day for 12 wks, followed by weekly for another 12 wks vs PBO. Efficacy & T-regs expansion were dose dependent. On to Phase 3 @RheumNow https://t.co/L0rYr5D1R1
      Late Breaker: Phase 2 RCT of low dose IL2 in SLE

      Dose dependent response in SRI4 over 12 weeks
      & surprisingly high

      Mike Putman EBRheum

      3 months ago
      Late Breaker: Phase 2 RCT of low dose IL2 in SLE Dose dependent response in SRI4 over 12 weeks & surprisingly high rates of LLDAS Too early to know if useful, but worth evaluating in a phase 3 #ACR25 @RheumNow Abstr#LB01 https://t.co/oPOLG82nwi
      The CAR T engine doesn’t stop!LB04: Phase 1 bispecific CD19/BCMA CAR T in refractory autoimmune disease 🚗💥✅

      Akhil Sood MD, MS AkhilSoodMD

      3 months ago

      The CAR T engine doesn’t stop! LB04: Phase 1 bispecific CD19/BCMA CAR T in refractory autoimmune disease 🚗💥 ✅ Low AEs (mostly Gr 1–2 CRS, hematologic) 💪 Robust efficacy in lupus nephritis 🔄 Deep B-cell depletion → naïve B-cell repopulation @RheumNow #ACR25

      HCQ weight-based dosing: out
      HCQ whole blood monitoring: in

      Whole blood levels more precisely balance risks of SLE flar

      Brian Jaros, MD Dr_Brian_MD

      3 months ago
      HCQ weight-based dosing: out HCQ whole blood monitoring: in Whole blood levels more precisely balance risks of SLE flare (under-dosing) vs. toxicitiy (over-dosing) Many pt on <5 mg/kg had supra-therapeutic blood levels with risk for toxicity @RheumNow #ACR25 #ACRBest Abst 1722 https://t.co/qIbACxAW39
      The ACR Convergence 2025 in Chicago opens with engaging topics curated for the global rheumatologist. As a clinician, I always look forward to sessions that provide updates and practical key points that I can bring home and apply to my practice.
      Pooled data fr diff SLE cohorts by Dr SGarg et al were evaluated to determine an upper threshold tx range of HCQ

      750-1

      sheila RHEUMarampa

      3 months ago
      Pooled data fr diff SLE cohorts by Dr SGarg et al were evaluated to determine an upper threshold tx range of HCQ 750-1150 ng/mL: safe & effective HCQ levels >1150ng/mL-supratx, no added tx benefit CKD st >/=3: 2x ⬆️odds of toxic hcq levels #ACR25 @RheumNow Abs1722 #ACRBest https://t.co/RFx1VO0bov
      #1723 Why is systemic autoimmunity more common in females?
      Loss of X-chromosome inactivation maintenance in B cells (not

      Mrinalini Dey DrMiniDey

      3 months ago
      #1723 Why is systemic autoimmunity more common in females? Loss of X-chromosome inactivation maintenance in B cells (not T cells) amplifies interferon-driven disease, with increased autoantibodies, inflammation and renal injury. Key mechanistic advance. @RheumNow #ACR25
      3rd plenary session!

      #1722 Defining safe HCQ levels in SLE: whole-blood 750-1150ng/mL= therapeutic range; >1150ng/mL

      Mrinalini Dey DrMiniDey

      3 months ago
      3rd plenary session! #1722 Defining safe HCQ levels in SLE: whole-blood 750-1150ng/mL= therapeutic range; >1150ng/mL ➡️ ~2× toxicity risk; <750ng/mL ➡️ higher flare risk CKD ≥3 increases odds of supratherapeutic levels New era of precision monitoring in SLE? @RheumNow #ACR25
      Plenary 3, HCQ blood levels in SLE

      HCQ level > 1150: 1.9x risk of HCQ toxicity
      HCQ level < 750: 1.4x risk of act

      Mike Putman EBRheum

      3 months ago
      Plenary 3, HCQ blood levels in SLE HCQ level > 1150: 1.9x risk of HCQ toxicity HCQ level < 750: 1.4x risk of active SLE HCQ dose < 5mg/kg: 1.9x risk active SLE My take home? Blindly reducing dose to <5mg/kg is BAD; use levels instead! @RheumNow #ACRBest #ACR25 Abstr1722 https://t.co/UCBPAKAyon
      ×